Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow-to-Debt Ratio
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow-to-Debt Ratio of 0.14x as of September 2025, meaning its operating cash flow of ₩2.62 Billion could theoretically repay 0% of its total liabilities (₩18.23 Billion) in one year. See 012790 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sinil Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Sinil Pharmaceutical Co. Ltd across 11 annual periods. For the full cash flow conversion analysis, see Sinil Pharmaceutical Co. Ltd (012790) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for Sinil Pharmaceutical Co. Ltd. Check 012790 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.17x | ₩22.69 Billion | ₩19.36 Billion | ▲ +35.9% |
| 2023 | 0.86x | ₩15.15 Billion | ₩17.56 Billion | ▲ +23.3% |
| 2022 | 0.70x | ₩13.69 Billion | ₩19.55 Billion | ▼ -1.1% |
| 2021 | 0.71x | ₩11.16 Billion | ₩15.78 Billion | ▲ +10.8% |
| 2020 | 0.64x | ₩11.06 Billion | ₩17.33 Billion | ▼ -13.9% |
| 2019 | 0.74x | ₩12.31 Billion | ₩16.59 Billion | ▼ -9.5% |
| 2018 | 0.82x | ₩9.19 Billion | ₩11.22 Billion | ▲ +9.5% |
| 2017 | 0.75x | ₩8.67 Billion | ₩11.59 Billion | ▼ -32.8% |
| 2016 | 1.11x | ₩12.09 Billion | ₩10.86 Billion | ▲ +5.8% |
| 2015 | 1.05x | ₩9.56 Billion | ₩9.09 Billion | ▲ +2.1% |
| 2014 | 1.03x | ₩9.33 Billion | ₩9.06 Billion | — |